A carvedilol to bisoprolol interchange program was carried out in a Singapore hospital with substantial cost savings of US$116 per patient-year without increase in adverse outcomes.
Doreen S. Tan, PharmD, BPharm, BCPS (AQ Cardiology)
Advertisement
Articles by Doreen S. Tan, PharmD, BPharm, BCPS (AQ Cardiology)
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5